MARKET

PRTA

PRTA

Prothena
NASDAQ
23.58
-0.03
-0.13%
After Hours: 23.54 -0.04 -0.17% 17:08 07/19 EDT
OPEN
23.68
PREV CLOSE
23.61
HIGH
24.11
LOW
23.04
VOLUME
325.37K
TURNOVER
0
52 WEEK HIGH
73.14
52 WEEK LOW
18.69
MARKET CAP
1.27B
P/E (TTM)
-7.2507
1D
5D
1M
3M
1Y
5Y
1D
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
NASDAQ · 6d ago
Weekly Report: what happened at PRTA last week (0708-0712)?
Weekly Report · 6d ago
Weekly Report: what happened at PRTA last week (0701-0705)?
Weekly Report · 07/08 09:15
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
NASDAQ · 07/03 12:34
June 2024 New Analysts Cover Uber, TG Therapeutics, CarMax, And More
21 new analysts joined Seeking Alpha in June and are highlighted today. They cover a range of sectors including biotech, technology, consumer staples, and real estate. New analysts cover Uber, TG Therapeutics, CarMax, Grab Holdings, and more. Each is highlighted with their first-ever investment thesis on Seeking Alpha.
Seeking Alpha · 07/02 17:00
Weekly Report: what happened at PRTA last week (0624-0628)?
Weekly Report · 07/01 09:15
Prothena Price Target Maintained With a $28.00/Share by RBC Capital
Dow Jones · 06/26 15:12
RBC Capital Reiterates Sector Perform on Prothena Corp, Maintains $28 Price Target
Benzinga · 06/26 15:05
More
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Webull offers Prothena Corporation PLC stock information, including NASDAQ: PRTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRTA stock methods without spending real money on the virtual paper trading platform.